Tuesday, November 13, 2012

Stanford team wins $20K for algorithm aimed at Lou Gehrig's disease drug trials

›
Lester Mackey. A team from Stanford University won $20,000 for its work with algorithms that could reduce the number of Lou Gehrig’s Dis...

Pearl Therapeutics grabs $65M in VC funding, moves COPD drug toward Phase III trials

›
Its main competition is seeking approval of a treatment for the lung disease COPD, but the leaders of Pearl Therapeutics Inc., and investo...
Monday, November 12, 2012

Nation's HIV research general Tony Fauci: Cure in 'discovery phase'

›
Dr. Tony Fauci. As director of the National Institute of Allergy and Infectious Diseases for the past 28 years, Tony Fauci has seen the ...
1 comment:

Stanford self-healing skin could someday shield smartphones

›
If all goes according to plan for researchers at Stanford University, a new synthetic skin technology could have big implications for both t...

New wave of local companies tackles Lou Gehrig's disease

›
Patrizia Fanara and David Fineman of KineMed. Hoping to find clues for unlocking potentially lucrative cures to diseases such as Alzheim...

Buck Institute, partner spawn startup

›
Stelios Tzannis and Brian Kennedy. The Buck Institute for Research on Aging and a for-profit partner are spinning out their research int...
Wednesday, November 7, 2012

Cerus to pursue U.S. approval of plasma safety system

›
The Food and Drug Administration will allow Cerus Corp. to submit a premarket application toward approval of its blood safety system, the co...
Tuesday, November 6, 2012

Latest Genentech breast cancer drug, T-DM1, faces FDA decision by Feb. 26

›
Genentech Inc.'s experimental cancer drug T-DM1 is heading for a Feb. 26 decision date with the Food and Drug Administration. The Sout...
Monday, November 5, 2012

Pharmacyclics stock sags on disappointing clinical results

›
Cancer drug maker Pharmacyclics Inc.’s stock dropped almost 20 percent at one point Monday, after it released disappointing trial data. P...

Nile Therapeutics CEO takes 99.6% cut in pay -- but maybe not for long

›
Nile CEO Dr. Darlene Horton. Dr. Darlene Horton is taking one in the pocket book for the Nile Therapeutics Inc. team -- at least for the...

Pathworks Diagnostics names Lee McCracken as CEO

›
Lee McCracken has been named chief executive officer of Pathworks Diagnostics Inc. The Redwood City-based cancer diagnostics company  said...

BioMarin shares rise on data from late-stage rare disease trial

›
BioMarin CEO Jean-Jacques Bienaime. BioMarin Pharmaceutical Inc. will seek regulatory approval early next year of a drug to treat a crip...
Friday, November 2, 2012

UCSF partners schizophrenia treatments

›
Bob Bennett and Rachel Loewy. Innovative treatment for schizophrenia by the Family Service Agency and researchers at UC San Francisco sh...

BNBuilders see project growth in health care, colleges

›
BNBuilders' David Becker (left) and Sean Truesdale. David Becker and Sean Truesdale, principals at BNBuilders Inc.'s Redwood Cit...
2 comments:

Patients' tales, biotech legends add weight to BayBio awards

›
Genentech co-founder Herb Boyer. When two or more biotechs are gathered, you hear the usual phrases, including the old standby, “We'...
33 comments: